Healthcare >> Analyst Interviews >> December 13, 1999

Photodynamic Therapy : Samuel Gerszonowicz – Hcfp Brenner Securities

SAMUEL (GERSZON) GERSZONOWICZ is a Research Analyst and Director with HCFP/Brenner Securities, where he specializes in the biopharmaceutical industry. He covers biotechnology and pharmaceuticals with special emphasis in the drug-device arena. Prior to joining the firm, Mr. Gerszonowicz was associated with Johnson Research & Capital, as well as with MacDougall, MacDougall and MacTier, Inc., where he served as Corporate and Investment Financial Advisor. He has contributed his expertise in business development, investment/corporate finance, and informatics to management and stakeholders for more than 20 years. Mr. Gerszonowicz holds a Bachelor's degree in Economics and Genetics from the University of Alberta, Canada. He includes skiing, hiking, archeology, philosophy, and jazz among his personal interests. Profile
TWST: Samuel, what is PhotoDynamic Therapy, and why do you refer to it

as third millennium TechnoScience?

Mr. Gerszonowicz: PhotoDynamic Therapy describes the technology and

protocols involved